现代药物开发是一项团队活动
我们的药物开发团队一直与合作伙伴就 250 多项计划保持良好合作，范围涵盖开发的各个阶段以及从肿瘤学到罕见病的各个治疗领域。
作为您的专职管家，我们的最佳实践、定量和一体化方法可以节省大量时间和成本，同时加快申报和商业成功。从临床药理学到定量药理学，再到监管提交和策略以及市场准入，我们在全球拥有 650 多名知名专家，致力于实现您的目标。与 Certara 一起建立您的药物开发梦之队。
我们如何为客户提供帮助
定量系统安全与毒理学 (QSTS)
QSTS 用于辅助表征药物不良反应。相对于传统的经验终点和基于动物的测试，QSTS 将作用方式描述为药物副作用的信号通路和受干扰的机体生物信号传导网络。
利用我们在建模和模拟、法规科学和市场准入方面的一流能力，我们与您的团队一起指导关键决策，并为您在监管和商业上取得成功做好准备。
敏捷、沟通、质量和信任对于我们合作伙伴关系的成功至关重要。我们携手成为一个一体化且有凝聚力的团队，以便一同预测风险、制定可靠的战略并实现无缝执行。
Dr. Patrick F. Smith is President, Certara Drug Development Solutions, where he leads a global team of drug development scientists that creates value for clients across the entire life cycle and ultimately accelerates patient access to medicines. 凭借逾 20 年的药物开发经验，Patrick 拥有药物开发各个阶段的工作经验，在传染病、肿瘤学和炎症，以及新颖的早期开发方案设计，乃至应用建模和模拟来解决关键开发问题方面都具有深厚的专业知识。
Rik 的主要经验在于，在整个开发过程中，将基于模型的各个环节与整体临床药理学和临床开发交付成果一体化。他喜欢结合自己的分析能力和创造力来设计有效的药物开发策略，以在适当的时间解决适当的问题。
Mr. Schemick has served as Senior Vice President, Corporate Operations and Integration since 2023 年 4 月 1 日 and focuses on building operational excellence as Certara continues to grow. From August 2014 through March 2023, he served as Chief Financial Officer. Mr. Schemick brings 19 years of financial management experience to the company in a wide range of industries, including software and consulting organizations. Before Certara, Schemick served as Vice President of Financial Planning and Analysis for Haights Cross Communications, a holding company for education and media investments, playing a key role in business transformation, strategy, and financial operations on behalf of private equity investors. Schemick also held Chief Financial Officer roles for two divisions of Kaplan Inc, a leading education company, and has significant experience in both public and private equity backed enterprises. Schemick started his career at Arthur Andersen after graduating with an MBA in accounting from Rutgers University. In addition, he has earned the titles of CPA and CTP.
Dr. Patrick F. Smith is President, Certara Drug Development Solutions, where he leads a global team of drug development scientists that creates value for clients across the entire life cycle and ultimately accelerates patient access to medicines. 凭借逾 20 年的药物开发经验，Patrick 拥有药物开发各个阶段的工作经验，在传染病、肿瘤学和炎症，以及新颖的早期开发方案设计，乃至应用建模和模拟来解决关键开发问题方面都具有深厚的专业知识。
Rik 的主要经验在于，在整个开发过程中，将基于模型的各个环节与整体临床药理学和临床开发交付成果一体化。他喜欢结合自己的分析能力和创造力来设计有效的药物开发策略，以在适当的时间解决适当的问题。
Mr. Schemick has served as Senior Vice President, Corporate Operations and Integration since 2023 年 4 月 1 日 and focuses on building operational excellence as Certara continues to grow. From August 2014 through March 2023, he served as Chief Financial Officer. Mr. Schemick brings 19 years of financial management experience to the company in a wide range of industries, including software and consulting organizations. Before Certara, Schemick served as Vice President of Financial Planning and Analysis for Haights Cross Communications, a holding company for education and media investments, playing a key role in business transformation, strategy, and financial operations on behalf of private equity investors. Schemick also held Chief Financial Officer roles for two divisions of Kaplan Inc, a leading education company, and has significant experience in both public and private equity backed enterprises. Schemick started his career at Arthur Andersen after graduating with an MBA in accounting from Rutgers University. In addition, he has earned the titles of CPA and CTP.
